A Phase 1, Single-Center, Open-Label Study to Evaluate the Pharmacokinetics and Tolerability of Rilzabrutinib (PRN1008) in Japanese and Caucasian Healthy Male and Female Subjects
Latest Information Update: 11 Jun 2024
At a glance
- Drugs Rilzabrutinib (Primary)
- Indications Asthma; Autoimmune disorders; Chronic urticaria; Idiopathic thrombocytopenic purpura
- Focus Pharmacokinetics
- Sponsors Principia Biopharma
- 11 Jun 2024 New trial record